TradeFlare's AI research teams analysed SRRK on 15 market nights between April 27, 2026 and July 22, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| July 22, 2026 | BUY | $50.88 | — / — | +1.6% | +17.0% | FDA acceptance of apitegromab BLA resubmission. |
| July 17, 2026 | BUY | $51.73 | $59.53 / $43.97 | -9.8% | -0.6% | The positive fundamental and sentiment outlook, coupled with a technical oversold signal, suggests a potential short-to-medium term bounce. |
| June 29, 2026 | BUY | $54.76 | $65.94 / $46.71 | +2.9% | -10.2% | The stock is breaking out to new highs with strong technical and fundamental support, suggesting a multi-week trend continuation. |
| June 24, 2026 | BUY | $51.27 | $57.42 / $43.58 | +1.0% | -5.5% | The positive fundamental and sentiment catalysts, particularly the FDA BLA acceptance, suggest potential upside over the coming weeks. |
| May 27, 2026 | BUY | $51.51 | — / — | -11.8% | +6.2% | The stock is currently consolidating near resistance and requires a clear breakout signal. |
| May 19, 2026 | BUY | $49.35 | $57.00 / $41.95 | +6.5% | -1.3% | The stock is consolidating near resistance, and a clear catalyst is needed for a decisive move. |
| May 18, 2026 | BUY | $49.35 | $57.00 / $41.95 | +8.7% | -3.8% | The stock is consolidating near resistance, and a clear catalyst is needed for a decisive move. |
| May 15, 2026 | BUY | $51.28 | — / — | -2.5% | -7.0% | PDUFA action date for apitegromab on September 30, 2026. |
| May 6, 2026 | BUY | $47.13 | — / — | +6.5% | -3.8% | Resubmission of key drug application to the FDA. |
| May 5, 2026 | HOLD | $46.48 | — / — | +4.4% | -5.3% | Successful BLA resubmission and subsequent approval. |
| May 4, 2026 | BUY | $46.37 | — / — | +4.0% | -3.9% | Positive clinical trial data for apitegromab. |
| April 30, 2026 | BUY | $46.30 | — / — | -0.3% | +5.8% | Successful BLA resubmission for apitegromab. |
| April 29, 2026 | BUY | $46.73 | — / — | +1.8% | +7.6% | FDA approval of apitegromab for SMA. |
| April 28, 2026 | BUY | $46.29 | — / — | +0.9% | +8.4% | FDA decision on the resubmitted BLA for the SMA drug. |
| April 27, 2026 | HOLD | $46.48 | — / — | +0.4% | +11.3% | FDA approval of apitegromab for Spinal Muscular Atrophy (SMA). |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.